Protein–protein interaction in insulin signaling and the molecular mechanisms of insulin resistance

Antti Virkamäki, Kohjiro Ueki, and C. Ronald Kahn

Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts 02215, USA

Address correspondence to: C. Ronald Kahn, Joslin Diabetes Center, One Joslin Place, Boston, Massachusetts 02215, USA. Phone: (617) 732-2635; Fax: (617) 732-2593; E-mail: kahnr@joslab.harvard.edu

Insulin is an anabolic hormone with powerful metabolic effects. The events after insulin binds to its receptor are highly regulated and specific. Defining the key steps that lead to the specificity in insulin signaling presents a major challenge to biochemical research, but the outcome should offer new therapeutic approaches for treatment of patients suffering from insulin-resistant states, including type 2 diabetes.

The insulin receptor belongs to the large family of growth factor receptors with intrinsic tyrosine kinase activity. Following insulin binding, the receptor undergoes autophosphorylation on multiple tyrosine residues. This results in activation of the receptor kinase and tyrosine phosphorylation of a family of insulin receptor substrate (IRS) proteins. These substrates are commonly referred to as docking proteins, since several other intracellular proteins bind to the phosphorylated substrates, thereby transmitting the signal downstream. Like other growth factors, insulin uses phosphorylation and the resultant protein–protein interactions as essential tools to transmit and compartmentalize its signal. These intracellular protein–protein interactions are pivotal in transmitting the signal from the receptor to the final cellular effect, such as translocation of vesicles containing GLUT4 glucose transporters from the intracellular pool to the plasma membrane, activation of glycogen or protein synthesis, and initiation of specific gene transcription (Figure 1).

In this article, we review some of our current understanding about early insulin signal transduction through the network of IRS interacting proteins and the mechanisms that may modify insulin signal transduction in insulin-resistant states, especially obesity and type 2 diabetes.

Protein–protein interactions

Some of the best-characterized protein interaction domains involved in insulin signaling are the PH (pleckstrin homology), PTB (phosphotyrosine binding), SH2, and SH3 domains (1) (Table 1). Other, less-characterized domains (e.g., LIM, PDZ, NOTCH, and WW) may also prove to be relevant (2). These interaction domains exist in the natural tertiary structure of proteins. In other cases, the domains for interaction are created by post-translational covalent modification of the protein. The most common examples of the latter are the effects of phosphorylation of proteins on tyrosine or serine/threonine residues and the lipid modification by prenylation or fatty acid acylation.

Figure 2 illustrates how signal transduction is transmitted from the receptor downstream using different types of domains. PH domains, which are found in most of the proteins that interact with the insulin receptor, bind to charged headgroups of specific phosphatidylinositides and are thereby targeted preferentially to membrane structures. PH domains in the IRS proteins target the proteins to the membrane adjacent to the insulin receptor (3). PTB domains, also found in IRS proteins, recognize the phosphotyrosine in the amino acid sequence asparagine-proline-any amino acid-phosphotyrosine (NPXpY), often present in tyrosine kinase receptors, including insulin receptor (4, 5).

Most of the intracellular partners of the insulin receptor substrates contain Src homology 2 (SH2) domains. These domains are also phosphotyrosine binding cassette but tend to have higher binding affinity than PTB domains and recognize specific amino acid patterns, making a more rigid protein–protein interaction possible. SH2...
domains consist of roughly 100 amino acids, including a highly conserved phosphorysine binding pocket (FLAVRES sequence) (6). The specificity of the binding is regulated by the few amino acids COOH-terminal to the phosphorysine. The SH2 domains of PI3-kinase recognize at least four pYMXM motifs in tyrosine-phosphorylated IRS-1. The SH2 domain of the adaptor protein Grb-2 and the SH2 domain of the phosphotyrosine phosphatase SHP-2 bind other sequences, including pYVNI, pYIDL, and pYASI sequences (1). In addition to these adaptor proteins, other SH2 proteins, such as Crk (adaptor), Nck (adaptor), Fyn (tyrosine kinase), and Csk (tyrosine kinase), bind to tyrosine residues on IRS proteins through their specific SH2 domains. SH3 domains are often present in these SH2 adaptor proteins. SH3 domains bind to proline-rich sequences with the consensus sequence PXXP with a specific helix structure and provide a link between the adaptor protein and its downstream targets or associated catalytic subunits (6).

Figure 2: Protein–protein interaction domains involved in insulin signal transduction. A typical IRS protein contains a PH domain, which targets the protein in plasma membrane, and a PTB domain, which binds to NPXpY motif in the β subunit of the insulin receptor. SH2 domains of SH2 adaptors and SH2 enzymes bind to multiple phosphotyrosines of IRS proteins. SH2 adaptors frequently possess SH3 domains that recognize PXXP motifs of other intracellular proteins, leading to further downstream signal transduction.

Insulin receptor substrates

Insulin receptor substrates are a growing family of proteins that are phosphorylated by the activated insulin receptor. To date, nine members of this family have been identified, including IRS-1 (17, 18), IRS-2 (19), IRS-3 (20), and IRS-4 (21), which are generally viewed as the most specific for insulin signaling; Gab-1 (22); Shc, which has three isoforms (23); and p62dok (24). Figure 2 shows the relationship between structure and function of a typical IRS protein. The PH domain of an IRS protein, involved in the targeting of the IRS proteins to the membrane and the insulin receptor, is found in all proteins in this family, except the Shc. All of the substrates, except Gab-1, have a PTB domain located just COOH-terminal to the PH domain. The PTB domain critical for recognition of the NPXY sequence in the insulin receptor. Thus, in most substrates, both a PTB domain and a PH domain contribute to the interaction with the receptor, presumably cooperating with other domains in IRS pro-
teins. From the functional point of view, all proteins in this family bind to the autophosphorylated insulin receptor only transiently and then dissociate, after which they can be recognized by SH2 domains of several proteins (Table 2). During interaction with the insulin receptor, the IRS proteins are phosphorylated on several tyrosine residues by the insulin receptor, creating binding sites for multiple SH2 domain proteins (1).

Shc binds to the activated insulin receptor and is phosphorylated by a mechanism similar to IRS-1. Shc contains a special PTB domain, which makes phosphorylation possible even without a PH domain. Also, unlike other members of the insulin receptor substrate family, Shc contains only a single phosphorylation site that binds an adaptor protein, Grb-2. This can lead to activation of a Ras/MAP kinase (MAPK) pathway and stimulation of the mitogenic signaling pathway (23). Compared with other growth factor stimuli, insulin is a weak stimulator of Shc tyrosine phosphorylation.

Gab-1 is a high-molecular-weight protein, like the IRS proteins, that contains a PH domain and several phosphorylation sites but has no PTB domain. Gab-1 is heavily phosphorylated by the epidermal growth factor receptor, but poorly by the insulin receptor (22). The biological function of Gab-1 is unknown, although it is expressed in many mammalian tissues.

p62 \text{dok} was originally described as a protein that could be phosphorylated by several receptor tyrosine kinases (24), including the insulin receptor; however, its role in insulin signaling has not been determined. Recently, phosphorylated p62 \text{dok} was demonstrated to associate with the GTPase-activating protein (GAP) for Ras. Since phosphorylated p62 \text{dok} does not have any putative PI3-kinase binding sites, it is unlikely to have a role in the metabolic actions of insulin.

Grb-IR is a recently discovered SH2 domain protein that may translocate from the cytosol to the plasma membrane and bind directly to the tyrosine-phosphorylated insulin receptor (25). Grb-IR binds to the critical NPEpY960 in the juxtamembrane region of the insulin receptor through its SH2 domain. It also contains an additional binding site located in the phosphorylated kinase activation loop of the insulin receptor but is only very slightly phosphorylated by insulin receptor. Overexpression of Grb-IR inhibits insulin- and IGF-1-induced mitogenic effects, as well as PI3-kinase activation. It is not known whether it acts solely as an inhibitor of insulin receptor or whether its interaction with the insulin receptor has distinct cellular effects.

### SH2 adaptor proteins

SH2 adaptor proteins recognize and bind to tyrosine-phosphorylated proteins by their SH2 domains. They do not possess intrinsic enzymatic activity but relay the ligand signal by additional protein–protein interactions. The regulatory subunits of PI3-kinase, as well as Grb2, are well-known examples of adaptor proteins. However, several other potentially important adaptor proteins have been described (Table 2). Since many of these were identified as cellular homologues of oncogenes, they are represented by three-letter acronyms, such as Crk and Nck.

### PI3-kinase regulatory subunits

PI3-kinase is a lipid kinase and a key element in the pathway leading to metabolic effects of insulin. PI3-kinase consists of a regulatory subunit responsible for binding to insulin receptor substrates and a catalytic subunit responsible for phosphorylation of phosphatidylinositols found in cellular membranes. There are at least eight different isoforms of the regulatory subunit. Six are derived by alternative splicing of the p85 \text{a} gene. These include p85 \text{a} (26), AS53 (also called p55 \text{a}) (27, 28), and p50 \text{a}, each of which occurs with and without a spliced insert (27). Two other isoforms, p85 \text{b} (26) and p55 \text{prk} (29), are derived from separate genes. Each of these regulatory subunits associates with IRS proteins in response to insulin and transduces the signal from IRS proteins to PI3-kinase activation. Whereas p85 \text{a} is ubiquitously expressed and thought to be responsible for ligand-dependent PI3-kinase signaling in many tissues, the other regulatory subunit isoforms are differentially expressed in various tissues (27, 28). Thus, each regulatory subunit might have a specific function dependent on its specific affinity to IRS proteins and ability to regulate PI3-kinase activity. It is also possible that each isoform participates in specific subcellular compartmentalization.

Inhibition of PI3-kinase activity using a dominant-negative mutant (30), or pharmacological agents such as wortmannin or LY294002 (31), abolishes insulin-stimulated glucose uptake and inhibits GLUT4 vesicle translocation to the plasma membrane. Many other cellular effects of insulin, such as antilipolysis, activation of fatty acid synthesis, acetyl CoA-carboxylase, glycogen synthase, Akt phosphorylation, glycogen synthase

---

**Table 1**

<table>
<thead>
<tr>
<th>Domain</th>
<th>Recognition motif or structure</th>
<th>Function in insulin signaling</th>
</tr>
</thead>
<tbody>
<tr>
<td>PH domain</td>
<td>Lipid products (PIP(_2), PIP(_3))</td>
<td>Recruitment of IRS proteins to the insulin receptor</td>
</tr>
<tr>
<td>PTB domain</td>
<td>Specific phosphotyrosine residue (NPXpY motif)</td>
<td>Recognition of the insulin receptor by IRS proteins</td>
</tr>
<tr>
<td>SH2 domain</td>
<td>Specific phosphotyrosine residue determined by three amino acids</td>
<td>Signal transmission from IRS proteins to downstream molecules</td>
</tr>
<tr>
<td>SH3 domain</td>
<td>COOH-terminal from the tyrosine protein-rich motif</td>
<td>Signal transmission from SH2 proteins to downstream molecules</td>
</tr>
</tbody>
</table>
kinase 3β inactivation, and stimulation of protein synthesis and DNA synthesis, are also inhibited by PI3-kinase suppression (32).

PI3-kinase is activated by many other hormonal stimuli, which do not mimic insulin action. This raises the question, what are the insulin-specific features of PI3-kinase activation? Figure 3 shows some of these features. First, in contrast to other growth factors, the insulin receptor does not bind PI3-kinase directly but rather uses docking proteins, such as IRS proteins, as a relay mechanism. This results in activation of PI3-kinase in a different compartment of the cell than is the case of other growth factors. Indeed, translocation of PI3-kinase activity from the cytosol to intracellular membranes has been reported following insulin stimulation (33, 34). Second, the membrane surface area of the endoplasmic reticulum is large and thus has a greater pool of lipid substrates for PI3-kinase than the plasma membrane. Thus, it is possible that in vivo, insulin signal produces more PI3-kinase products than other hormones (34).

Grb2. Grb2 is one of the best-characterized SH2 adaptor proteins. Grb2 is a 27-kDa molecule with an SH3–SH2–SH3 domain structure (Figure 2) (35). Grb2 constitutively associates with Sos, the guanine nucleotide exchange factor for plasma membrane–bound Ras (36). Docking of Grb2 to IRS proteins recruits Sos to Ras, resulting in activation of its GTPase (37). This leads to subsequent activation of the serine/threonine kinase cascade known as the MAPK cascade. This cascade relays the signal from the plasma membrane to the nucleus and is the essential signaling pathway for mitogenesis.

In most growth factor receptor signaling pathways, Grb2 binds to a tyrosine residue on the receptor or the substrate Shc through its SH2 domain in a phosphorylation-dependent manner. Following insulin stimulation, Grb2 binds to both IRS proteins and to Shc, and it is not clear which pathway is more important for its activity (37, 38). In either case, the Grb2/Shc complex does not seem to be tightly fixed to the plasma membrane in response to insulin. This might contribute to the relatively weak mitogenic effect of insulin as compared with other growth factor–dependent signaling. Grb2 has also been reported to associate with other guanine nucleotide exchange factors, such as C3G, that may be involved in e-Jun kinase activation (39, 40).

Crk and Nck. IRS proteins also bind several other adaptor proteins and proto-oncogenes whose roles are just beginning to unfold. Crk was originally identified as an oncogene product v-Crk. The cellular homologues of v-Crk are known as Crk-I (SH2–SH3 domain structure) and Crk-II (SH2–SH3–SH3) and are derived by alternative splicing from a single gene (41). Crk has been reported to associate with tyrosine-phosphorylated proteins, such as p130Cas and paxillin (42, 43), involved in the rearrangement of cytoskeletal components, through its SH2 domain. Recently, Crk has also been shown to bind to IRS-1 in an insulin-dependent manner (44). Crk uses its SH3 domains to bind to the guanine nucleotide exchange factors Sos and C3G, the latter of which activates the c-Jun kinase, leading to induction of transformation (40).

Nck is a 47-kDa multidomain protein with an SH3–SH2–SH3 domain structure. Nck associates with IRS-1 (45), many different tyrosine kinases, several serine/threonine kinases through its SH2 domain, as well as Sos through its SH3 domains (46–48). Since overexpression of Nck results in transformation of cells, Nck may transmit the mitogenic signals from IRS proteins by interacting with these kinases and Sos.

SH2 enzymes

SH2 enzymes bind to tyrosine-phosphorylated proteins through their SH2 domains but also possess an intrinsic catalytic domain (usually a kinase or phosphatase domain). A large group of these proteins belong to a family of proto-oncogenes, or protein kinases regulating mitogenesis, including Fyn, c-Cbl, and Csk. Other SH2 domain partners of IRS proteins may modulate PI3-kinase activity (SHIP) or the level of tyrosine phosphorylation (SHIP-2) by producing dephosphorylation of their representative substrates (Table 2). In general, the catalytic activity of each these SH2 enzymes is increased upon binding to the phosphorylated IRS proteins.

Fyn/Cbl/CAP complex. Fyn is a cytoplasmic protein tyrosine kinase that can be activated by association with other photophosphorylated proteins through its SH2 domain or by dephosphorylation of its COOH-terminal tyrosine. Fyn is not activated directly by the insulin receptor, but rather by interaction with IRS-1 (49) and another insulin receptor substrate, c-Cbl (50). The latter protein contains a PTB domain and binds to SH2 adaptor proteins Grb2, Crk, and the p85 subunit of PI3-kinase; however, its physiological role still remains unclear (51). c-Cbl is tyrosine-phosphorylated, binds to Fyn upon insulin stimulation, and is translocated to small invaginations of the plasma membrane, called caveolae, after insulin stimulation (50). Recently, it was shown that Fyn is one of the kinases responsible for the phosphorylation of caveolin (50, 52), a protein present in caveolae. Insulin is unique in its ability to phosphorylate both isoforms of caveolin; this does not occur in response to other growth factors (50).

It has also been demonstrated

### Table 2

<table>
<thead>
<tr>
<th>SH2 domain proteins</th>
<th>Non-SH2 domain proteins</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adapter proteins (associated proteins)</td>
<td>Adaptors/Chaperons</td>
</tr>
<tr>
<td>p85, A533 and p50 (p110 catalytic subunit)</td>
<td>14-3-3 proteins</td>
</tr>
<tr>
<td>Grb-2 (Sos)</td>
<td>Transforming proteins</td>
</tr>
<tr>
<td>Crk (p130Cas, C3G)</td>
<td>SV40 large T antigen</td>
</tr>
<tr>
<td>Nck (p130cas, C3G)</td>
<td>Structural proteins</td>
</tr>
<tr>
<td>Enzymes (effectors or target proteins)</td>
<td>Integrons</td>
</tr>
<tr>
<td>Fyn (Caveolin)</td>
<td>Ca++ATPase (SERCA1, SERCA2)</td>
</tr>
<tr>
<td>Csk (FAK)</td>
<td></td>
</tr>
</tbody>
</table>
that a c-Cbl–associated protein (CAP) that has three sequential SH3 domains is specifically expressed in insulin-responsive cell types and associates with both c-Cbl and the insulin receptor (53). Thiazolidinediones (TZDs), the class of insulin sensitizers that act through the nuclear receptor PPAR-γ, increase CAP expression levels and c-Cbl phosphorylation significantly in adipocytes (54), possibly contributing to their insulin-sensitizing effect.

**Csk.** The COOH-terminal Src kinase (Csk) is a cytoplasmic tyrosine kinase that inactivates Src-type kinases by tyrosine phosphorylation (55). Csk has been reported to associate with IRS-1 through its SH2 domain and promote dephosphorylation of the focal adhesion kinase (FAK) in an insulin-dependent manner (56). FAK is one of the key players for cell–cell interaction and cell–extracellular matrix interaction in integrin and other growth factor signaling pathways. Thus, it is likely that Csk is involved in the insulin-induced rearrangement of cytoskeletal components by altering FAK activity in insulin signaling (57).

**SHIP.** PI3-kinase activation produces PIP2 and PIP3. These are thought to act as second messengers for some biological responses of insulin and other growth factors by binding to PH domains of downstream molecules, such as serine/threonine kinases Akt/PKB and their activator PDK1 (58, 59). Recently, a 145-kDa protein, SHIP (SH2-containing inositol 5-phosphatase), has been identified as a specific phosphatase for 5'-phosphate of PIP3 and PIP3, converting the latter to PIP2 (60). Overexpression of SHIP by microinjection inhibits insulin-induced glucose transport and DNA synthesis, suggesting that PIP3, rather than PIP2, is the major mediator of PI3-kinase–dependent biological actions of insulin (61). SHIP contains multiple interaction domains with an SH2-phosphatase-NPXY-NPXY proline-rich domain structure. SHIP becomes tyrosine-phosphorylated following stimulation of cells with insulin, growth factors, and cytokines, after which it binds to the PTB domain of Shc. In the case of insulin, it is unclear whether SHIP associates with IRS proteins or the insulin receptor, although a recent report has demonstrated SHIP association with IRS-2 in response to erythropoietin (62).

**SHP-2.** SHP-2 (previously known as SH-PTP2, PTP1D, or Syp) is a phosphotyrosine phosphatase that binds to the COOH-terminal phosphotyrosines of IRS proteins (63). It has two SH2 domains and is ubiquitously expressed. Based on in vitro studies with phosphotyrosine peptides corresponding to the binding site of SHP-2, the phosphatase activity of SHP-2 is increased upon binding to IRS-1. The physiological substrates for SHP-2 are not known, but overexpression of SHP-2 modulates cell adhesion and migration, as well as insulin activation of the Ras/MAP-kinase pathway (64, 65).

**Proteins interacting with IRS proteins by unknown mechanisms**

There are a number of proteins that associate with IRS proteins by unknown mechanisms. These proteins include adaptors (14-3-3 proteins), transforming proteins (SV40 large T antigen), structural proteins (integrins), and enzymes (the Ca²⁺ ATPases SERCA1 and SERCA2) (Table 2).

14-3-3 proteins were originally shown to activate tryptophan/tyrosine hydroxylases and modulate protein kinase C activity (66). Recently, 14-3-3 proteins have been found to associate with several oncogene products and cell-cycle control proteins, although roles of these interactions are still unclear (67). Several isoforms of 14-3-3 proteins (β, ε, and ζ) have also been shown to associate with IRS-1, presumably through one of the several RXRXXpS motifs of IRS-1. Since these motifs are located in the PTB domain and close to the XXXM motifs, it is possible that the interaction between 14-3-3 and IRS proteins modulates the recognition of IRS proteins by the insulin receptor or the PI3-kinase activity associated with IRS proteins (68, 69).

The large T antigen of SV40 is a multifunctional protein that is essential in both the virus lytic cycle and the oncogenic transformation of cells by SV40 (70). IRS-1 and SV40 associate in a manner critical for the transformation process. IRS-1 and SV40 large T-antigen proteins are capable when coexpressed, but not by themselves, of inducing oncogenic transformation (71). In some cells, this process is regulated by IGF-1.
Insulin and IGF-1 stimulation also promote association between IRS-1 and αβ3 integrin (vitronecetin receptor) (72). In smooth muscle cells, blocking ligand occupancy of αβ3 integrin reduces IGF-1–induced IRS-1 phosphorylation (73). Recently, β1 integrins have also been reported to enhance IRS-1 phosphorylation and interaction, but not glucose transport, with downstream molecules such as PI3-kinase and Akt (74). These results suggest that integrins and insulin/IGF-1 receptor signaling pathways converge at an early point in the signaling cascade around the IRS proteins.

The Ca2+ ATPase of adult fast-twitch skeletal muscle (SERCA1) has also been shown to interact with tyrosine-phosphorylated IRS-1 by expression screening (75). A similar interaction also occurs with SERCA2 (cardiac muscle isoform). Both of these associate with IRS-1 and IRS-2 through an SH2-like domain and the pYGSS motif on the IRS proteins. Since an inhibitor against SERCA induces apoptosis in some cell lines (76), the IRS/SERCA complex might be involved in an insulin- and IGF-1–dependent antipapoptotic effect.

Alterations in protein–protein interactions in insulin-resistant states

As we learn more and more about the regulation of the insulin signaling network, a key question is, how is insulin signaling regulated in the pathophysiology of human disease? Recent studies in both animals and human tissues have demonstrated that both genetic and nongenetic factors can regulate insulin signaling by changing the sequence, expression level, or covalent modification of proteins involved in the intracellular network of insulin action.

Genetic alterations in the insulin signaling proteins

Insulin receptor. Naturally occurring mutations of the insulin receptor are rare, and the phenotype, when present, is usually a syndrome of extreme insulin resistance, such as leprechaunism or the type A syndrome of insulin resistance and acanthosis nigricans. Since the first reports in 1988 (77, 78), over 100 such cases have been identified. Genomic analysis has indicated that mutations of the insulin receptor itself do not play an important role in the pathophysiology of typical type 2 diabetes or obesity. For a complete review of this subject, see ref. 79.

IRS-1. IRS-1 was the first insulin receptor substrate identified and the first to be found to have multiple natural polymorphisms (80–84). Polymorphisms of IRS-1 are significantly more common in type 2 diabetic patients than in controls and include the G972R (glycine 972→arginine), S892G, G819R, R1221C, and A513P variants (80, 81). Of these, the G972R polymorphism is the most common and has been studied most extensively. This polymorphism is found in Caucasian populations, with a prevalence of 5.8% in normal and 10.7% in type 2 diabetic patients, respectively. In Caucasian populations, obese carriers of this polymorphism show decreased insulin sensitivity during an oral glucose tolerance test, and an individual homozygous for the codon 972 mutation had a diabetic response to dexamethasone challenge. The polymorphism G972R does not occur in Pima Indians (85).

Because the G972R polymorphism is associated with type 2 diabetes, lies between two potential tyrosine phosphorylation sites involved in binding of the p85 subunit of PI3-kinase, and potentially interferes with PI3-kinase binding to IRS-1, a series of in vitro experiments have been performed to explore the molecular effects of this sequence change (86). Indeed, expression of G972R variant of IRS-1 in 32D(IR) cells causes a specific defect in binding of the p85 subunit of PI3-kinase to IRS-1, and a 36% decrease in IRS-1–associated PI3-kinase activity (86). Insulin-stimulated IRS-1 tyrosine phosphorylation is normal, consistent with the idea that G972R interferes with the interaction between IRS-1 and the SH2 domains of PI3-kinase. The net effect is a 35–40% decrease in insulin’s final biological effect in these cells: stimulation of mitogenesis.

In Japanese type 2 diabetic patients, several additional polymorphisms have been described, including P190R, M209T, and S809F polymorphisms, and silent nucleotide variants L142 and G625 A804 (82). While the prevalence of each of these polymorphisms alone is not different between patients and healthy controls, the combined prevalence of these polymorphisms, along with the G972R polymorphism, is threefold greater compared with healthy controls (29.5 vs. 8.5%; P < 0.05). In vitro, 32D cells expressing these variants also show reduced PI3-kinase activation (87). In a euglycemic, hyperinsulinemic clamp, the insulin sensitivity in the carriers versus noncarriers of these polymorphism carriers is decreased 29.5% in type 2 diabetics and 22% in healthy subjects.

Other insulin receptor substrates and PI3-kinase. Recently, two polymorphisms in IRS-2 have been described in the Caucasian population: a substitution of G1057D and G879S. Amino acid polymorphisms of IRS-4 are also common in the Caucasian population. However, neither of these polymorphisms is associated with type 2 diabetes or insulin resistance (88, 89).

A common polymorphism of the p85α subunit of PI3-kinase changes methionine in position 326 to isoleucine. In one study, 31% of Caucasians carried the mutation in its heterozygous form and 2% in its homozygous form. This polymorphism occurs in a region between the SH3 domain and the first SH2 domain, but the functional effects have not been studied in vitro. Although the frequency is not increased in diabetes, homozygous individuals do exhibit a 32% reduction in insulin sensitivity compared with wild-type and heterozygous carriers in an intravenous glucose tolerance test (90).

Other modulators of insulin signaling

Peroxisome proliferator–activated receptor γ (PPAR-γ). PPAR-γ is a nuclear receptor that appears to be an important regulator of adipogenesis (91). PPAR-γ has two isoforms, γ1 and γ2. PPAR-γ1 is ubiquitously expressed, whereas PPAR-γ2 is expressed mainly in adipose tissue (91). Although PPAR-γ is not directly a part of the insulin signaling pathway, insulin sensitizers, such as troglitazone and pioglitazone, bind to PPAR-γ with high affinity, activating the regulation of gene transcription. A rare, naturally occurring mutation of PPAR-γ (P115Q) in the immediate vicinity of an important regulatory phosphorylation site results in a constitutively active PPAR-γ (92). Carriers of this mutation suffer from...
extreme obesity without significant insulin resistance. In vitro, overexpression of PI115Q in 3T3-L1 fibroblasts leads to rapid differentiation into adipocytes. Therefore, this rare form of obesity results from a constitutively active form of PPAR-γ, which leads to increased adipogenesis but simultaneously sensitizes the whole body to insulin action. Interestingly, another mutation in the unique region PPAR-γ2 (P12A) was recently reported to be associated with lower body mass index and improved insulin sensitivity (93).

Plasma cell differentiation factor-1 (PC-1). PC-1 is a membrane glycoprotein with ectonucleotide pyrophosphatase activity that seems to act as an intrinsic inhibitor of insulin receptor tyrosine kinase activity (94, 95). In healthy subjects with no clinically significant defects in glucose metabolism, PC-1 expression in muscle negatively correlates with insulin sensitivity in intravenous insulin tolerance test and in vitro stimulation of muscle insulin receptor tyrosine kinase activity (96, 97). It has been reported that PC-1 overexpression in skeletal muscle of obese subjects explains downregulation of insulin receptor tyrosine phosphorylation better than it does the decrease in insulin receptor expression, but this requires further investigation (98). Whether genetic factors regulate the expression level of PC-1 is not known.

Rad. Rad (Ras associated with diabetes) was originally cloned as a message overexpressed in the skeletal muscle of type 2 diabetic patients (99). Rad belongs to a unique branch of the Ras superfamily of GTPases and in vitro has a GTP-hydrolyzing activity (99). The Rad gene, designated RAD1, has been found to contain certain trinucleotide repeat polymorphisms. Based on the number of trinucleotide repeats found in RAD1, 10 alleles can be divided into four subclasses, I–IV. The minor classes (I, II, and IV) of RAD1 are associated with type 2 diabetes in the Caucasian population (100). Some individuals with type 2 diabetes have been identified with a high expression level of Rad. In cultured myotubes and adipocytes, overexpression of Rad decreases insulin-dependent glucose uptake (101). Rad is also an insulin-regulated gene (102).

Acquired factors

Obese human subjects have decreased insulin receptor expression level and tyrosine kinase activity in skeletal muscle (103) and adipocytes (104). Similar findings have been reported in type 2 diabetic patients in skeletal muscle (103) and the liver (105).

Insulin receptor expression is regulated by rates of synthesis, internalization, and degradation, whereas its tyrosine kinase activity is, in addition, regulated by post-translational modifications of the receptor, especially serine/threonine and tyrosine phosphorylation. Both insulin receptor expression and tyrosine kinase activities are restored by weight loss, which also improves insulin sensitivity. In type 2 diabetes, however, the restoration of insulin sensitivity is not complete, suggesting the existence of an additional postreceptor defect of insulin signaling (106). In animal models of both genetic and acquired obesity, insulin receptor number in the liver is decreased and can be corrected by ameliorating hyperinsulinemia (107). These data suggest that downregulation of insulin receptor expression and tyrosine kinase activity is secondary to obesity, or more likely, hyperinsulinemia, which accompanies it. In addition to decreased insulin receptor expression and tyrosine kinase activity, however, several additional mechanisms may contribute to the insulin resistance associated with obesity, including changes in membrane lipids secondary to hyperlipidemia (108).

Less is known about the exact sites of postreceptor resistance in obesity and diabetes. In severely obese patients (body mass index of 52 kg/m²), IRS-1 expression level in skeletal muscle is reduced to 54% of that in nonobese patients (109). In the less-obese type 2 diabetic patients, IRS-1 expression appears to be reduced in adipocytes (110) but unaltered in skeletal muscle (111, 112). IRS-2 expression, on the other hand, is not altered in adipocytes, where it becomes the main docking protein for PI3-kinase (110). Despite these variable data concerning IRS protein expression, the uniform finding is that IRS-1-associated tyrosine phosphorylation and PI3-kinase activity is decreased in skeletal muscle and adipocytes both in obesity and type 2 diabetes (109–112). In both genetic (113–116) and induced (117, 118) rodent models of obesity, insulin-stimulated phosphorylation of the insulin receptor and IRS-1 is decreased in muscle.

Additional alterations in the insulin signaling cascade found in hyperinsulinemic models of obesity include alternative splicing of the PI3-kinase regulatory subunits in the liver (114, 115). Downregulation in the p85α and a twofold increase in the p50α expression are found in both leptin-deficient ob/ob mice (115) and in Zucker fatty rats (114). AS53 in the liver of ob/ob mice is dramatically upregulated, whereas in Zucker fatty rats, it is downregulated by approximately 50%. This might affect the routing or compartmentalization of the insulin signal in these models. Whether changes in alternative splicing of PI3-kinase regulatory subunits also occur in human obesity is not known.

Hyperinsulinemia. Hyperinsulinemia is the classic indicator of insulin resistance and may itself contribute to the insulin resistance in type 2 diabetes and obesity. Amelioration of hyperinsulinemia in animal models by streptozotocin corrects insulin receptor expression levels (107). Moreover, insulin receptor levels are normal or only mildly impaired in type 1 diabetes (119, 120) and are generally increased in animal models of hypoinsulinemic diabetes (120). These data suggest that downregulation of the insulin receptor occurs as a result of increased internalization and degradation after insulin binds to its receptor, thus leading to secondary insulin resistance (106).

Counterregulatory hormones and adrenergic system. Counterregulatory hormones (epinephrine, norepinephrine, cortisol, glucagon, and growth hormone) play a significant role in antagonizing insulin action after hypoglycemia (121). It is not clear whether increased sympathetic nervous system activity, commonly found in insulin resistance syndrome (122), contributes to decreased insulin signaling. However, in brown adipocytes (Klein, J., and Kahn, C.R., unpublished data) and white adipocytes (123), stimulation of the β-adrenergic receptor decreases insulin-stimulated PI3-kinase activity. Desensitization of β-adrenergic receptors by isoproterenol increases insulin-stimulated glucose uptake.
in white adipocytes (124). A naturally occurring mutation of the β3-adrenergic receptor (W64R) has been associated with increased abdominal obesity and early-onset type 2 diabetes (125), although this remains controversial. In isolated human omental adipocytes, the W64R variant shows decreased β agonist–induced lipolysis (126), providing a hypothesis as to why omental adiposity may be increased in patients carrying this variant.

_Tumor necrosis factor-α (TNF-α)._ TNF-α was first identified as an endogenous cytokine produced by macrophages and lymphocytes after inflammatory stimulation. TNF-α is expressed in many types of cells, including adipose tissue (127, 128). Adipocytes of obese animals and humans overexpress TNF-α in positive correlation to body mass index and hyperinsulinemia, and weight reduction decreases TNF-α expression (127–130). Although this local release of TNF-α has little effect on systemic TNF-α concentrations, local concentrations of free and membrane-bound TNF-α are likely to be increased in obesity. TNF-α appears to impair insulin signaling by increasing serine phosphorylation of IRS-1 (and possibly other IRS proteins) (127, 128, 131). Serine-phosphorylated IRS-1 inhibits insulin receptor tyrosine kinase activity, which leads to impaired downstream signaling (128). It has been hypothesized that TNF-α–induced serine phosphorylation of IRS-1 causes an additional insulin receptor inhibitory factor (possibly a tyrosine phosphatase or an inhibitory factor (possibly a tyrosine phosphatase or an

**Glucose and other nutrients.** Hyperglycemia itself impairs tissue insulin sensitivity, as well as insulin secretion from the pancreatic β cells, a phenomenon commonly known as glucose toxicity (139). In type 1 diabetic patients, 24 hours of hyperglycemia decreases insulin sensitivity 26–35% in a subsequent euglycemic, hyperinsulinemic clamp (140). In type 1 diabetic patients (141) and partially pancreatectomized diabetic rats (142), correction of hyperglycemia normalizes insulin sensitivity. There are currently two major theories explaining hyperglycemia–induced insulin resistance: the hexosamine pathway and the activation of protein kinase C.

Following its uptake, 2–4% of glucose is shunted to the hexosamine pathway by the enzyme glutamine:fructose-1,6-diphosphate amidotransferase (GFA) (143). Infusion of glucosamine into rats bypasses the GFA reaction and induces insulin resistance but does not further impair insulin resistance in partially pancreatectomized rats (144, 145). This suggests that glucosamine and hyperglycemia share a common mechanism leading to insulin resistance (144). The increased flux through the hexosamine pathway increases tissue concentration of a hexosamine metabolite, UDP-GlcNAc, which correlates closely with the observed induction of insulin resistance (146). This may lead to O-linked glycosylation of proteins on serine and threonine residues, and thus compete with serine and threonine phosphorylation of these sites (143). Several nuclear transcription factors, of which Sp1 is the best characterized, are among the targets of this glycosylation (147). This provides a mechanism by which hyperglycemia could interfere with insulin and other signaling transduction pathways that are regulated by serine and threonine phosphorylation. Activation of the hexosamine pathway may also occur by free fatty acids, uridine, or overexpression of GFA, and result in insulin resistance (148, 149). The ability of a variety of nutrients to activate the hexosamine pathway has led to the theory that this pathway serves as a general nutrient sensing pathway, through which hyperglycemia or hyperlipidemia could decrease insulin sensitivity of cells when nutrient excess prevails (148). In cell culture, omission of glutamine (a cofactor of GFA) from the media, or addition of glutamine analogues, blunts the desensitizing effect of glucose on insulin sensitivity (150). Glucosamine infusion for two to six hours will decrease insulin-stimulated IRS-1 tyrosine phosphorylation, PI3-kinase activation, and activation of glycogen synthase in a manner that parallels the decrease in insulin-stimulated glucose uptake in skeletal muscle. This effect can be seen both in acute and chronic stimulation with insulin (151) (Patti, M.E., personal communication).

Protein kinase C (PKC) is a serine kinase that has a number of potential substrates, including the insulin receptor (152). PKC is activated by the intracellular metabolite diacylglycerol (DAG), the concentration of which increases in a glucose-dependent manner during exposure of isolated muscles to hyperinsulinemia (153). In NIH3T3 cells overexpressing the insulin receptor, insulin desensitization by glucose can be blocked by PKC inhibitors and thiazolidinediones (154). PKC activation by DAG can lead to serine phosphorylation of the insulin receptor, a mechanism similar to the effect of TNF-α.
Although the resulting insulin resistance can be blocked differentially by PKC inhibitors, which do not block TNF-α–induced insulin resistance, or by PTPase inhibitors, which do not block PKC-induced insulin resistance (156). In vivo data showing that inhibition of PKC reduces hyperglycemia-induced insulin resistance is still, however, lacking. It is likely that the activation of PKC is important in the development of diabetic microvascular complications (157), and thus, PKC inhibitors are now under intense investigation as potential therapy for diabetic microvascular complications.

Phosphotyrosine phosphatases (PTPases). PTPases are responsible for dephosphorylation of the insulin receptor and its substrates, and hence, turning off the insulin signal. To date, no insulin receptor–specific phosphatase has been identified. Total membrane-bound tyrosine phosphatase activity is increased in skeletal muscle of type 2 diabetic patients (158). Immunodepletion experiments in muscles from these diabetic patients and obese individuals suggest that especially two phosphatases, protein-tyrosine phosphatase 1B (PTP-1B) and leukocyte antigen–related (LAR) phosphatase, are mainly responsible for this increase (159). The insulin receptor and IRS-1 are dephosphorylated by both of these phosphatases, and therefore, they are candidate targets for therapeutic interventions to increase insulin sensitivity (160).

Lessons from knockout animal models

Evaluating how insulin sensitivity affects whole body glucohomeostasis has been a major challenge for diabetes research. One approach has been to use targeted disruption of several insulin signaling proteins, such as the insulin receptor, IRS-1, and IRS-2. Targeted disruption of the insulin receptor is lethal after a few days of birth in homozygous animals, whereas heterozygous animals have almost no phenotype (161, 162). Disruption of IRS-1 results in retarded growth (due to IGF-1 resistance), but only mild insulin resistance and impaired glucose tolerance without diabetes (163, 164). Disruption of IRS-2 also leads to insulin resistance, but in this case, there is also a reduction in β-cell mass, leading to diabetes (165). Combination of the heterozygous insulin receptor knockout with the heterozygous IRS-1 knockout leads to more severe insulin resistance and a phenotype that includes a delayed onset of diabetes similar to human type 2 diabetes (166). This is a pure form of insulin resistance with elevated insulin levels. Interestingly, only about 40% of these mice develop diabetes, suggesting the importance of additional background genes.

Tissue-specific disruption of the insulin receptor gives a more detailed view of how glucose homeostasis is regulated in a tissue-specific manner in vivo. Muscle-specific disruption of the insulin receptor (MIRKO) in mice results in severe insulin resistance in isolated skeletal muscles, but at the whole body level, glucose tolerance is near normal (74). Indeed, the major metabolic disturbances found in the MIRKO mouse are increased body fat, elevated triglycerides, and slightly elevated free fatty acid levels. β-cell–specific disruption of the insulin gene (βIRKO) has a more severe phenotype than the MIRKO, with severely impaired glucose tolerance and a loss of first-phase insulin secretion in the glucose tolerance test (167). These animal models demonstrate that insulin serves an important role in β-cell function and suggest that insulin resistance at the β-cell level may contribute to the altered insulin secretion in type 2 diabetes. Additional data from these and other models should help us to clarify how glucose homeostasis is regulated and define some defects in signaling proteins responsible for insulin resistance in type 2 diabetes.

Table 3
Molecular mechanisms of insulin resistance and their relationship to insulin-resistant states in humans

<table>
<thead>
<tr>
<th>Genetic</th>
<th>Proteins involved</th>
<th>Polymorphisms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sequence alterations</td>
<td>Insulin receptor</td>
<td>Over 100 mutations described</td>
</tr>
<tr>
<td></td>
<td>IRS-1</td>
<td>G972R, S862G, G819R, R1221, A513P</td>
</tr>
<tr>
<td></td>
<td>PI 3-kinase</td>
<td>M326</td>
</tr>
<tr>
<td>Level of expression</td>
<td>Insulin receptor</td>
<td>Promoter mutations, half-life effects</td>
</tr>
</tbody>
</table>

Acquired

<table>
<thead>
<tr>
<th>Protein involved</th>
<th>Mechanism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decreased protein level</td>
<td>Insulin receptor</td>
</tr>
<tr>
<td></td>
<td>IRS-1, IRS-2</td>
</tr>
<tr>
<td>Decreased tyrosine phosphorylation</td>
<td>Insulin receptor</td>
</tr>
<tr>
<td></td>
<td>IRS-1</td>
</tr>
<tr>
<td>Increased serine phosphorylation</td>
<td>Insulin receptor</td>
</tr>
<tr>
<td></td>
<td>IRS-1</td>
</tr>
<tr>
<td>O-glycosylation</td>
<td>Transcription factors</td>
</tr>
<tr>
<td>Changes in membrane lipids</td>
<td>Insulin receptor</td>
</tr>
</tbody>
</table>

● Mechanism has in vivo evidence ○ Mechanism is putative but lacks in vivo evidence
Implications
It should be clear from this review that although the insulin signaling network is complex, modern cell biology and biochemistry are starting to turn this basic knowledge of the insulin signal transduction pathways into an understanding of how these pathways can be regulated in human disease. The challenge for basic research is to characterize the specific events that translate insulin binding to the diverse metabolic effects, and to reveal the nature of insulin resistance in the pathophysiology in various disease states.

Protein modification and protein–protein interactions provide a number of mechanisms by which insulin signal transduction can be impaired in type 2 diabetes. Regardless of the underlying mechanism, the resulting insulin resistance has diverse consequences. The main defects in type 2 diabetes are peripheral insulin resistance and insufficient compensation of pancreatic β cells. In the face of increased glucose output from the liver and decreased peripheral glucose utilization, the insufficient insulin secretion from the β cells results in glucose intolerance and frank diabetes. The question has been, which of the two defects—peripheral insulin resistance or β-cell insulin secretion—is the primary defect in type 2 diabetes (168)? The recent findings in mice with β-cell-specific disruption of the insulin receptor (βIRKO mice) suggests that impaired insulin secretion might be a result of insulin resistance in the β cells themselves (167). The loss of first-phase insulin secretion after glucose challenge seen in these mice resembles that seen in human type 2 diabetes (167). These data suggest that signals mediated by the insulin receptor are essential for the release of insulin secretory vesicles. Indeed, a combination of insulin resistance in muscle, liver, adipose tissue, and β cells may create the phenotype of type 2 diabetes.

What is the cause of insulin resistance in diabetes? The inheritable nature of the disease points out that genetic factors must exist. A vast number of candidate genes for glucose and lipid metabolism, as well as signaling proteins, have been tested, but no single major susceptibility gene for classical type 2 diabetes has been thus far identified. It is likely that type 2 diabetes consists of several subtypes of the disease, where a combination of different mechanisms impairs insulin sensitivity.

Table 3 summarizes molecular mechanisms that may play a role in some insulin-resistant states in humans. Most of these mechanisms are associated with insulin resistance in type 2 diabetes and obesity, and many of them are induced by environmental factors. Nevertheless, genetic defects of various steps of insulin signaling, even if relatively minor, could impair glucose homeostasis significantly when a environmental factors coexist. It is important not to underestimate the potential role of sequence polymorphisms in the signaling proteins associated with type 2 diabetes. Even if a single polymorphism can explain only a small fraction of the total insulin resistance, a combination of polymorphisms may account for the multifactorial nature of this disease. Therefore, an assortment of mild genetic defects that merely modify the insulin signaling cascade may be a more likely scenario for the inheritable defect and the coexisting precipitating factors, such as obesity, precipitate the phenotype of impaired glucose tolerance and diabetes. As the basic mechanisms of insulin signaling unfold, we will have increasing possibilities to specifically evaluate, and eventually modulate, these abnormalities.

Acknowledgments
This work was supported by National Institutes of Health grants DK-31036, DK-33201, and DK-45935. A. Virkamaki is the recipient of the Sigrid Juselius Fellowship and the Albert Renold Fellowship from the European Association for the Study of Diabetes.


50. Wary, K.K., Mariotti, A., Zurzolo, C., and Giancotti, F.G. 1998. A requirement for insulin receptor substrate proteins create a link between the tyrosine phosphorylation cascade and the Ca2+-ATPases in muscle and heart.


